Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.

Comabella M, Fernández-Arquero M, Río J, Guinea A, Fernández M, Cenit MC, de la Concha EG, Montalban X.

J Neuroimmunol. 2009 May 29;210(1-2):116-9. doi: 10.1016/j.jneuroim.2009.01.012. Epub 2009 Apr 5. Erratum in: J Neuroimmunol. 2009 Sep 29;214(1-2):132.

PMID:
19349081
2.

HLA class II and response to interferon-beta in multiple sclerosis.

Fernández O, Fernández V, Mayorga C, Guerrero M, León A, Tamayo JA, Alonso A, Romero F, Leyva L, Alonso A, Luque G, de Ramón E.

Acta Neurol Scand. 2005 Dec;112(6):391-4.

PMID:
16281922
3.

Human leukocyte antigen class I and class II genes polymorphisms might be associated with interferon α therapy efficiency of chronic hepatitis B.

Zhu X, Du T, Wu X, Guo X, Niu N, Pan L, Xin Z, Wang L, Li Z, Li H, Liu Y.

Antiviral Res. 2011 Mar;89(3):189-92. doi: 10.1016/j.antiviral.2011.01.001. Epub 2011 Jan 15.

PMID:
21241740
4.

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.

Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E, Florio C, Pirozzi G, Lanzillo R, Ferrante P, Vivo P, Mini M, Macrì M, Orefice G, Lombardi ML.

Neurology. 2001 Dec 11;57(11):1976-9.

PMID:
11739812
5.

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL.

PLoS One. 2008 Apr 2;3(4):e1927. doi: 10.1371/journal.pone.0001927.

6.

Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C.

Airoldi A, Zavaglia C, Silini E, Tinelli C, Martinetti M, Asti M, Rossini A, Vangeli M, Salvaneschi L, Pinzello G.

Eur J Immunogenet. 2004 Dec;31(6):259-65.

PMID:
15548263
7.

Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2.

Zipp F, Windemuth C, Pankow H, Dichgans J, Wienker T, Martin R, Müller C.

Hum Immunol. 2000 Oct;61(10):1021-30.

PMID:
11082515
8.

Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium.

Chao MJ, Barnardo MC, Lui GZ, Lincoln MR, Ramagopalan SV, Herrera BM, Dyment DA, Sadovnick AD, Ebers GC.

Hum Mol Genet. 2007 Aug 15;16(16):1951-8. Epub 2007 Jun 20.

PMID:
17584771
9.

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.

Samadzadeh S, Tabibian E, Sabokbar T, Shakoori A, Dehgolan SR, Armaki SA, Aslanbeigi B, Abolfazli R.

J Neurol Sci. 2015 May 15;352(1-2):37-40. doi: 10.1016/j.jns.2015.03.004. Epub 2015 Mar 9.

PMID:
25824849
10.

HLA class I and class II frequencies in patients with sarcoidosis from Croatia: role of HLA-B8, -DRB1*0301, and -DQB1*0201 haplotype in clinical variations of the disease.

Grubić Z, Zunec R, Peros-Golubicić T, Tekavec-Trkanjec J, Martinez N, Alilović M, Smojver-Jezek S, Kerhin-Brkljacić V.

Tissue Antigens. 2007 Oct;70(4):301-6.

PMID:
17767551
11.
12.

Human leukocyte antigens I and II haplotypes associated with human papillomavirus 16-positive invasive cervical cancer in Mexican women.

Hernández-Hernández DM, Cerda-Flores RM, Juárez-Cedillo T, Granados-Arriola J, Vargas-Alarcón G, Apresa-García T, Alvarado-Cabrero I, García-Carrancá A, Salcedo-Vargas M, Mohar-Betancourt A.

Int J Gynecol Cancer. 2009 Aug;19(6):1099-106. doi: 10.1111/IGC.0b013e3181a83cf4.

PMID:
19820376
13.

Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer.

Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L, Dalianis T, Bergfeldt K, Masucci GV.

Tissue Antigens. 2007 Sep;70(3):205-13.

PMID:
17661908
14.

Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.

Minagar A, Adamashvilli I, Jaffe SL, Glabus MF, Gonzalez-Toledo E, Kelley RE.

Ann N Y Acad Sci. 2005 Jun;1051:111-20.

PMID:
16126950
15.

HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.

Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, Inoko H, Akbari MT, Noroozi R, Hajilooi M, Solgi G.

Pharmacogenomics. 2016 Apr;17(5):489-98. doi: 10.2217/pgs.16.2. Epub 2016 Mar 29.

PMID:
27020477
16.

Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.

Ghabaee M, Bayati A, Amri Saroukolaei S, Sahraian MA, Sanaati MH, Karimi P, Houshmand M, Sadeghian H, Hashemi Chelavi L.

Cell Mol Neurobiol. 2009 Feb;29(1):109-14. doi: 10.1007/s10571-008-9302-1. Epub 2008 Aug 26.

PMID:
18726686
17.

Human leucocyte antigen DNA typing in Singaporean Chinese patients with Graves' disease.

Chan SH, Lin YN, Wee GB, Ren EC, Lui KF, Cheah JS.

Ann Acad Med Singapore. 1993 Jul;22(4):576-9.

PMID:
8257062
18.

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X.

Arch Neurol. 2009 Aug;66(8):972-8. doi: 10.1001/archneurol.2009.150.

PMID:
19667218
19.

HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine.

Amirzargar AA, Mohseni N, Shokrgozar MA, Arjang Z, Ahmadi N, Yousefi Behzadi M, Amanzadeh A, Shokri F.

Iran J Immunol. 2008 Jun;5(2):92-9. doi: IJIv5i2A3.

PMID:
18523354
20.

Susceptibility for multiple sclerosis is determined, in part, by inheritance of a 175-kb region of the TcR V beta chain locus and HLA class II genes.

Beall SS, Biddison WE, McFarlin DE, McFarland HF, Hood LE.

J Neuroimmunol. 1993 Jun;45(1-2):53-60.

PMID:
8101191

Supplemental Content

Support Center